
Hubert Dabire

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5185999/publications.pdf Version: 2024-02-01



HIIREDT DARIDE

#	Article	IF	CITATIONS
1	The hypertensive effect of sorafenib is abolished by sildenafil. Cardio-Oncology, 2020, 6, 7.	0.8	2
2	Development of original metabolically stable apelinâ€17 analogs with diuretic and cardiovascular effects. FASEB Journal, 2017, 31, 687-700.	0.2	48
3	Vascular and angiogenic activities of CORM-401, an oxidant-sensitive CO-releasing molecule. Biochemical Pharmacology, 2016, 102, 64-77.	2.0	68
4	Development of an Experimental Model to Study the Relationship Between Day-to-Day Variability in Blood Pressure and Aortic Stiffness. Frontiers in Physiology, 2015, 6, 368.	1.3	9
5	Comparative Effect of Hypothermia and Adrenaline During Cardiopulmonary Resuscitation in Rabbits. Shock, 2014, 41, 154-158.	1.0	6
6	Increased stiffness and cell–matrix interactions of abdominal aorta in two experimental nonhypertensive models. Journal of Hypertension, 2014, 32, 652-658.	0.3	17
7	Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. Cardiovascular Research, 2012, 95, 86-96.	1.8	32
8	Adiponectin negatively correlated with carotid arterial structure in the leptin-resistant Zucker diabetic fatty rat. Artery Research, 2012, 6, 12.	0.3	0
9	Vascular endothelial dysfunction in Duchenne muscular dystrophy is restored by bradykinin through upregulation of eNOS and nNOS. Basic Research in Cardiology, 2012, 107, 240.	2.5	40
10	Identification and pharmacological properties of E339–3D6, the first nonpeptidic apelin receptor agonist. FASEB Journal, 2010, 24, 1506-1517.	0.2	95
11	Arterial stiffness and the autonomic nervous system during the development of Zucker diabetic fatty rats. Diabetes and Metabolism, 2009, 35, 364-370.	1.4	17
12	Capillary endothelial but not lymphatic function is restored under rosiglitazone in Zucker Diabetic Fatty rats. Microvascular Research, 2009, 77, 220-225.	1.1	8
13	Aortic stiffness and pulse pressure amplification in Wistar-Kyoto and spontaneously hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2506-H2512.	1.5	42
14	Relationship between noradrenaline and nonlinear indexes of blood pressure dynamics in normotensive and spontaneously hypertensive rats. Fundamental and Clinical Pharmacology, 2004, 18, 643-648.	1.0	5
15	Arterial stiffness and angiotensinogen gene in hypertensive patients and mutant mice. Journal of Hypertension, 2004, 22, 1299-1307.	0.3	24
16	Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clinical Science, 2003, 105, 637-644.	1.8	24
17	Relationship Between Arterial Distensibility and Low-Frequency Power Spectrum of Blood Pressure in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2002, 39, 98-106.	0.8	21
18	Effects of autonomic blockers on linear and nonlinear indexes of blood pressure and heart rate in SHR. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H1113-H1121.	1.5	18

HUBERT DABIRE

#	Article	IF	CITATIONS
19	Impact of pulse pressure on degree of cardiac hypertrophy in patients with chronic uraemia. Journal of Hypertension, 2000, 18, 1645-1650.	0.3	15
20	Acute And Chronic Sympathoinhibition On Carotid Artery Diameter Of Spontaneously Hypertensive Rats: Effects Of Clonidine And Flesinoxan. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 715-723.	0.9	1
21	Long-term cardiovascular effects of high "osteoprotective" dose levels of 17 beta-estradiol in spontaneously hypertensive rats. Cardiovascular Drugs and Therapy, 2000, 14, 303-307.	1.3	12
22	Differential effects of tyrosine kinase inhibitors on contraction and relaxation of the aortas of normotensive and hypertensive rats. European Journal of Pharmacology, 1999, 374, 49-58.	1.7	12
23	Factors determining cardiac hypertrophy in hypertensive patients with or without peripheral vascular disease. Clinical Science, 1998, 95, 261.	1.8	3
24	Quantification of sympathetic and parasympathetic tones by nonlinear indexes in normotensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1290-H1297.	1.5	48
25	Use of nonlinear methods to assess effects of clonidine on blood pressure in spontaneously hypertensive rats. Journal of Applied Physiology, 1998, 84, 1795-1800.	1.2	14
26	Red blood cells participate in the metabolic clearance of catecholamines in the rat. Life Sciences, 1997, 60, 357-367.	2.0	5
27	Effects of Clonidine and Flesionoxan on Blood Pressure Variability in Conscious Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1997, 30, 241-244.	0.8	15
28	Mechanical Stress of the Carotid Artery at the Early Phase of Spontaneous Hypertension in Rats. Hypertension, 1997, 29, 992-998.	1.3	18
29	Carotid Arterial Changes Produced by a Centrally Mediated Antihypertensive Agent in Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1995, 26, 666-673.	0.8	7
30	Neuronal metabolism of catecholamines in pithed and electrically stimulated rats. Journal of the Autonomic Nervous System, 1995, 54, 41-48.	1.9	3
31	Henri Schmitt. Fundamental and Clinical Pharmacology, 1995, 9, 209-210.	1.0	0
32	Systemic and Regional Haemodynamic Effects of 1–(2, 5–Dimethoxy-4–IODO-Phenyl)-2–Aminopropane (DOI) and α-Methyl-5–HT, in the Anaesthetised Rat. Clinical and Experimental Hypertension, 1994, 16, 779-798.	0.5	9
33	Vascular and cardiac effects of α-methyl-5-HT and DOI are mediated by different 5-HT receptors in the pithed rat. European Journal of Pharmacology, 1993, 250, 67-75.	1.7	8
34	Pharmacological analysis of the cardiac effects of 5â€HT and some 5â€HT receptor agonists in the pithed rat. Fundamental and Clinical Pharmacology, 1992, 6, 237-245.	1.0	6
35	S14063: a new potent 5-HT1A receptor antagonist devoid of β-adrenoceptor blocidng properties. European Journal of Pharmacology, 1991, 203, 323-324.	1.7	6
36	Implication of the Central Nervous System in the Systemic and Regional Hemodynamics of Two Centrally Acting Hypotensive Drugs, Flesinoxan and Clonidine, in the Rat. Journal of Cardiovascular Pharmacology, 1991, 18, 605-613.	0.8	13

HUBERT DABIRE

#	Article	IF	CITATIONS
37	Hypotensive Effects of 5-HT1A Receptor Agonists on the Ventrolateral Medullary Pressor Area in Dogs. Journal of Cardiovascular Pharmacology, 1990, 15, S61-S67.	0.8	18
38	Ventrolateral medullary pressor area: site of hypotensive and sympatho-inhibitory effects of (±) 8-OH-DPAT in anaesthetized dogs. , 1990, , 343-346.		0
39	Ventrolateral medullary pressor area: site of hypotensive and sympatho-inhibitory effects of (±)8-OH-DPAT in anaesthetized dogs. European Journal of Pharmacology, 1989, 160, 385-394.	1.7	55
40	DOI is a mixed agonist-antagonist at postjunctional 5-HT2 receptors in the pithed rat. European Journal of Pharmacology, 1989, 170, 109-111.	1.7	12
41	Characterization of DOI, a putative 5-HT2 receptor agonist in the rat. European Journal of Pharmacology, 1989, 168, 369-374.	1.7	25
42	Vascular postsynaptic effects of some 5-HT1-like receptor agonists in the pithed rat. European Journal of Pharmacology, 1988, 150, 143-148.	1.7	10
43	Comparison of effects of some 5-HT1 agonists on blood pressure and heart rate of normotensive anaesthetized rats. European Journal of Pharmacology, 1987, 140, 259-266.	1.7	43
44	Pharmacological Properties of the Enantiomers of Idazoxan: Possible Separation between their Alpha-Adrenoceptor Blocking Effects. Clinical and Experimental Hypertension, 1986, 8, 387-409.	0.3	4
45	(Imidazolinyl-2)-2-Benzodioxane 1–4 (Idazoxan) and Its Stereoisomers, New α2-Antagonists. Journal of Cardiovascular Pharmacology, 1985, 7, S127-S129.	0.8	2
46	Stereoselectivity of central α-adrenoceptors involved in sleep induced by clonidine in chickens. Neuropharmacology, 1985, 24, 709-712.	2.0	5
47	Action of stereoisomers of (imidazolinyl-2)-2-benzodioxane-1-4 or 2-(2-(1,4-benzodioxanyl))-2-imidazoline (170 150; RX 781094) on peripheral presynaptic and central α2-adrenoceptors. European Journal of Pharmacology, 1982, 86, 83-86.	1.7	15
48	In vitro studies with (imidazolinyl-2)-2-benzodioxane-1-4 ((±)-170 150), a new potent α2-adrenoceptor blocking agent. European Journal of Pharmacology, 1982, 86, 87-90.	1.7	14
49	Interaction between mianserin and clonidine at ? 2-Adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1982, 318, 288-294.	1.4	12
50	A further attempt to characterize the α2-adrenoceptor blocking properties of (imidazolyl-2)-2-benzodioxane 1–4 (170 150) in pithed rats. European Journal of Pharmacology, 1981, 73, 367-370.	1.7	18